The current COVID-19 pandemic offers a unique opportunity to strengthen mechanisms that promote the use of drug repurposing processes -considering the drug safety profile and the possibility of originate different adverse reactions in patients with distinct concomitant diseases-; inclusively, in the ongoing or future clinical trials, having the potential to reduce the time and costs for finding potential solutions to the current pandemic. Additionally, contributing to future analysis for high threat pathogens and rare diseases. This idea is welcomed by some other authors who conveyed on the potential of drug repurposing for common national and global health benefits 118 . Between the several advantages of this process, the one which leads efforts to the use of the current information -on human pharmacology and toxicology-of safe and affordable generic drugs, is worth to remark. As also stated by Guy et al. , along with this statement, there is the urge to motivate the transparency and compliance of the highest ethical principles for the conduction of studies, including as a key potential for drug repurposing, the visualization and sharing of negative results. Mainly, promoting and assuring that well-designed randomized clinical trials are timely implemented, especially during health emergencies and crises. In this sense, drug repurposing will be fulfilling its main objective: proposing potential, prompt, cost-effective, and safe solutions for the public and global health problems, with a human-centered approach.